a New Jersey federal court's ruling that Amgen patents covering the drug were valid and that the proposed generics would infringe them.would have barred its generics until 2034.
Amgen bought Otezla from Celgene Corp in 2019 for $13.4 billion. Celgene sued several drugmakers over their proposed Otezla generics starting in 2018, and 17 of the 19 lawsuits have been settled since. Zydus and Sandoz appealed the decision that two of the infringed patents were valid. The Federal Circuit on Wednesday affirmed the ruling.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Corporate greed getting what it wants...
The list price of Otezla is over 4k for a thirty day supply.
sickening